Foghorn Therapeutics Inc.
NASDAQ:FHTX

Watchlist Manager
Foghorn Therapeutics Inc. Logo
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Watchlist
Price: 5.065 USD -1.46% Market Closed
Market Cap: 281.6m USD
Have any thoughts about
Foghorn Therapeutics Inc.?
Write Note

Foghorn Therapeutics Inc.
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Foghorn Therapeutics Inc.
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Depreciation & Amortization
$3.5m
CAGR 3-Years
38%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Depreciation & Amortization
$8.4B
CAGR 3-Years
-1%
CAGR 5-Years
34%
CAGR 10-Years
27%
Gilead Sciences Inc
NASDAQ:GILD
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Depreciation & Amortization
$5.6B
CAGR 3-Years
18%
CAGR 5-Years
23%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Depreciation & Amortization
$219.7m
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
13%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Depreciation & Amortization
$469.5m
CAGR 3-Years
20%
CAGR 5-Years
19%
CAGR 10-Years
25%
No Stocks Found

Foghorn Therapeutics Inc.
Glance View

Market Cap
281.6m USD
Industry
Biotechnology

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 119 full-time employees. The company went IPO on 2020-10-23. The firm's Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is initially focused on oncology. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, which is evaluating in separate Phase I studies in metastatic uveal melanoma and relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company is also developing FHD-609, a protein degrader, to treat synovial sarcoma is in phase I study. The firm is also engaged in developing additional programs targeting populations that include selective BRM and selective ARID1B modulators. Foghorn Securities Corporation is its subsidiary.

FHTX Intrinsic Value
6.126 USD
Undervaluation 17%
Intrinsic Value
Price

See Also

What is Foghorn Therapeutics Inc.'s Depreciation & Amortization?
Depreciation & Amortization
3.5m USD

Based on the financial report for Dec 31, 2023, Foghorn Therapeutics Inc.'s Depreciation & Amortization amounts to 3.5m USD.

What is Foghorn Therapeutics Inc.'s Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
54%

Over the last year, the Depreciation & Amortization growth was 5%. The average annual Depreciation & Amortization growth rates for Foghorn Therapeutics Inc. have been 38% over the past three years , 54% over the past five years .

Back to Top